It’s rare we get any peace and quiet these days. From the 24 news cycle to the bombardment of push notifications and personalised advertisements trying to capitalise on our insecurities and desires—it seems pretty healthy to want to take a break from it all every once in a while.
The usual response to getting away from it all is probably to take a hike up a mountain, or holiday away to somewhere sunny—although it looks like we won’t be doing that anytime soon, thanks to COVID. But what if I told you there was another way, which required minimal money, time or resources, to truly get away from it all? An experience that deprives us of any sensory encounters or responsibilities, to help us focus on ourselves and just ourselves for an hour or two. That’s where sensory deprivation tanks come in.
Sensory deprivation tanks come under many names; isolation tanks, float tanks, float cabins, and the list goes on. Essentially, it’s all the same concept: a pitch-black, light-proof, and soundproof container containing body-temperature salty water, designed to make you float and strip you completely of all senses. It all sounds like science fiction but float tanks have continued to grow in popularity over the recent decades.
The first isolation tank was developed by the neuropsychiatrist John C. Lilly in 1954, however, widespread interest in the technology came almost twenty years later, when Glenn Perry began selling commercial tanks along with the help of Lilly himself. As science has continued to show evidence that a sensory-deprived experience has physical and mental benefits, finding a sensory deprivation tank in your area is now just a Google search away. In fact, in my city of Manchester, finding a 2-hour sensory deprivation experience is easier than finding a decent kebab.
There are a number of reasons why people fork out the cash to deprive their mind completely of external senses. First, and probably the most obvious, is the novelty of the experience. In an era of social media, we’re constantly bombarded with new stimuli—many will agree with me that the idea of blocking away the outside world for a few hours, to focus only on ourselves, is quite appealing.
However, don’t be mistaken, the science behind sensory deprivation tanks is far from a novelty. Research has shown that a sensory-deprived floating session brings both physical and mental benefits, including better sleep, increased muscle relaxation, decreased pain, as well as lowering stress and anxiety.
Science also hints that sensory deprivation can improve focus and concentration, leading to clearer and more precise thinking. Ah, if only I knew this as a student, a few hours in the tank may have helped my brain, deprived of an attention span. Maybe then I wouldn’t have left my dissertation until the very last minute.
Likewise, in 2014, the European Journal of Integrative Medicine reported that sessions in a sensory deprivation tank can increase originality, imagination and intuition—all of which can lead to an enhancement of creativity.
It’s the burning question that I’ve always wondered: in an environment where you’re stripped of your senses, what’s it like to be on a substance that, on the contrary, enhances those senses while in the tank? It seems I’m not the only one to wonder about this either. The very man who brought float tanks into existence, Lilly, took a controversial turn in the 1960s when he started studying the effects of LSD and ketamine while inside a float tank.
Unfortunately, little research into the interaction of psychedelics and sensory deprivation tanks has been done since—presumably because of stricter law enforcement and regulation of drugs in the following decades. Yet again, the war on drugs, which has a mountain of evidence that it causes more harm than good, has acted as a giant roadblock for scientific discovery.
So, in the absence of peer-reviewed objective scientific data, I did what any good journalist would—turned to Reddit for answers. That was sarcasm, obviously, and it should be noted that these are isolated self-reported case studies from anonymous internet users, so do take what they’re saying with a pinch of salt.
One user, who reported taking a tab of acid before their session, said “due to the almost complete lack of sensory information coming in, my mind began to create its own reality around me. I was seeing myself sunken into a pinkish iridescent gelatin-like substance that had an indent perfectly shaped for my resting body.”
They continued, “it was also a very sensual and empowering experience when I ran my hands along my body. Given that I hadn’t truly seen myself for multiple hours, I felt beautiful. The way I felt under my own hands seemed ideal and I realised I really wouldn’t want to look any other way. I’ve recently lost quite a bit of weight and it made me feel somewhat unlike myself. This experience remedied any self-doubt regarding my physicality.”
Another user gave a less positive review on the experience. After completing two sessions in the tank while on psychedelics they said their third “scarred me, and threw me into a state of temporary psychosis that lasted several hours after leaving the tank because I just couldn’t shake that experience from my mind. I would rather not go into further detail, but suffice it to say that the most blissful moments of my first two experiences don’t begin to justify risking the horror of my third experience.”
Whether you want to undergo the experience while tripping balls is a question for you to ask yourself, and only you alone. Besides the obvious fact that psychedelic substances are illegal in the UK, I would never endorse someone to take the plunge unless they felt completely certain within themselves that they were ready for the experience—and I’d advise having previous experience with psychedelics outside of a sensory deprived tank full of water beforehand.
That being said, there is a wealth of compelling evidence to suggest that a sober sensory deprived experience can be incredibly beneficial both for your mental and physical wellbeing. It’s for this reason that more and more sensory deprivation tanks are popping up across the globe—and as our world becomes increasingly digitised creating more stimuli and shorter attention spans, they’re not going anywhere soon.
“We help patients unlock the healing power of the mind through Psychedelic Inspired Medicines & Experiential Therapies. Together we can overcome,” reads MindMed’s website. The company is known for discovering, developing, and deploying psychedelic-inspired medicines to improve health, promote wellness, and alleviate suffering in patients. And that’s not all, on Tuesday 27 April, the biotech company went public on the Nasdaq exchange under the ticker “MNMD.” Here’s how MindMed hopes to capture shares of those markets with its alternative, psychedelic offerings.
After its Nasdaq listing debut on Tuesday, MindMed became the latest psychedelic drug developer to use a major US exchange as a pathway to raise money and bring new mental illness and addiction treatments deeper into the mainstream. This listing means the stock now trades on the Nasdaq Capital Market as well as on the NEO Exchange in Canada.
“Shares surged 33 per cent over the counter on Monday ahead of Tuesday’s listing,” reported Investor’s Business Daily. But things didn’t exactly go to plan—in a public market where stocks can do no wrong, MindMed got torched by close, dropping as much as 30 per cent.
That didn’t stop CEO JR Rahn to stay hopeful about the future of the stock listing, who said in a statement that it would “increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately enhance long-term shareholder value.”
And MindMed’s future does seem interesting. The biotech company is working on an array of projects from LSD’s impact on anxiety and ADHD to a compound it calls 18-MC (a non-hallucinogenic synthetic derivative of ibogaine that is in trials for addiction treatment).
And according to an investor deck, industry stats are all good trips to get on. The global antidepressants market is expected to grow colossally in the next few years, from anxiety and ADHD drugs to depression and anti-addiction treatments.
Like many other psychedelic drug companies, none of MindMed’s major projects has generated revenue or profit yet. In a March filing, the company said it expects operating losses to continue and that it expects to incur “significant costs associated with its research and development initiatives.”
It makes sense then that it is looking for opportunities to garner more attention and money. Now, the question is: is the stock a risky buy currently? Although the global psychedelic drugs market has grown significantly in recent years due to an increasing prevalence of mental disorders, depression, and breakthroughs relating to psychedelic drugs, the market still faces considerable risk and uncertainties before it can secure the US’ FDA approvals.
On top of that, the stigma associated with the use of psychedelic drugs is also a big burden. As of now, the psychedelic drugs market remains at an early developmental stage, with most companies still executing clinical trials. This could hinder MindMed’s growth in the near term. “Although its pipeline projects look promising, there remains high uncertainty regarding its commercial prospects and value,” writes Entrepreneur.
The stock soared 773.9 per cent over the past year, mainly because of a surge in the popularity of psychedelic drugs. That being said, uncertainties regarding a timeline for potential FDA approval of its therapies could mean danger ahead. That’s why it would be wise to avoid the stock and simply enjoy psychedelics as a recreational drug for now. Looks like MindMed is about to go on a bad trip…